50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Leukemias - Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM

Hall A (Moscone Center)

DOCK180, a New Surrogate Marker to Distinguish CD34 Positive Acute Leukemia Cells from CD34 Positive Normal Hematopoietic Stem/Progenitor Cells

Mitsufumi Nishio, MD, PhD¹, Kohki Kumano, M.D., Ph.D.¹^*, Katsuya Fujimoto, M.D., Ph.D.¹^*, Tomoyuki Endo, M.D., Ph.D.¹^*, Satoshi Yamamoto, M.D., Ph.D.¹^*, Akio Shigematsu, MD, PhD²^*, Takeshi Kondo, MD., PhD³, Junji Tanaka, MD, PhD⁴, Satoshi Hashino³, Masahiro Imamura⁵, Hiroshi Nishihara, M.D., Ph.D.⁶^*, Norihiro Sato, M.D., Ph.D.⁷^* and Takao Koike, M.D., Ph.D.¹^*

¹Dept. of Medicine II, Hokkaido University, Sapporo, Japan
²Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
³Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
⁴Dept. of Hem. & Onc., Hokkaido University, Sapporo, Japan
⁵Dept of Hematol Hokkaido Univ Sch of Med, Sapporo, Japan
⁶Laboratory of Molecular and Cellular Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
⁷Translational Research and Clinical Trial Center, Hokkaido University Hospital, Sapporo, Japan

1477

Acute Lymphoblastic Leukemia (ALL) with t(8;14)(q11.2;q32): B-Lineage Disease with High Proportion of Down Syndrome. A Children’s Oncology Group (COG) Study

Yoav H. Messinger, MD¹, Rodney Higgins, PhD², Meenakshi Devidas, PhD³^*, Stephen P. Hunger, MD⁴, Andrew J. Carroll, PhD⁵ and Nyla A. Heerema, PhD⁶

¹Children's Hospitals and Clinics, Saint Paul, MN
²Allina Cytogenetics Lab, 17401, Abbott Northwestern Hospital, Minneapolis, MN
³Department of Epidemiology & Health Policy Research, University of Florida College of Medicine, Gainesville, FL
⁴University of Colorado Denver School of Medicine and The Children's Hospital, Aurora, CO
⁵Department of Genetics, University of Alabama at Birmingham, Birmingham, AL
⁶Ohio State University, Columbus, OH

1478

Expression of the Cell Polarity Protein PTK7 in Acute Myeloid Leukaemia

Thomas Prebet, MD¹^*, Anne Catherine Lhoumeau, PharmD²^*, Christine Arnoulet, PharmD³^*, Sylvie Marchetto, Ingeneer³^*, Christian Chabannon, MD, PhD⁴, Danielle Sainty, MD³^*, Norbert Vey, MD⁵ and Jean Paul Borg, PharmD, PhD²^*

¹Molecular Pharmacology, INSERM U891 Centre de Recherche en CancÃƒÂ©roligie de Marseille, Marseille, France
²Molecular Pharmacology, INSERM U891 Centre de Recherche en Cancéroligie de Marseille, Marseille, France
³Biopathology Department, Institut Paoli Calmettes, Marseille, France
⁴Centre of Biological Ressources, Institut Paoli Calmettes, Marseille, France
⁵Dept. of Hematology, Institut Paoli Clamettes, Marseille, France

1479

A New Human CD20 Spliced mRNA as a Potential Molecular Marker for the Follow-up of B-Cell Malignancies

Marina Deschamps¹^*, Carole Henry¹^*, Eric Robinet²^*, Francine Garnache-Ottou¹^*, Jean-Paul Remy-Martin¹^*, Christophe Borg¹^*, Pierre-Simon Rohrlich³^*, Eric Deconinck⁴^*, Pierre Tiberghien⁵ and Christophe Ferrand¹^*

¹INSERM UMR645 - EFSBFC - IFR133, Besancon, France
²Virology, INSERM UMR478, Strasbourg, France
³Hematology-Pediatry, INSERM UMR645 - CHU Jean Minjoz, Besançon, France
⁴Hematology, INSERM UMR645 - CHU Jean Minjoz, Besançon, France
⁵Etablissement Francais du Sang, Besancon, France

1480

Stimulation of B-Cell Lymphoproliferations with CpG-Oligonucleotide DSP30 Plus IL-2 Is More Effective than with TPA to Detect Clonal Abnormalities

Stéphanie Struski¹^*, Carine Gervais¹^*, Catherine Helias¹^*, Raoul Herbrecht, MD², Bruno Audhuy³^* and Laurent Mauvieux, MD, PhD⁴

¹Laboratoire d'Hématologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
²Oncology and Hematology, Hopital de Hautepierre, Strasbourg Cedex, FRA
³Service d'Onco-Hématologie, Hôpitaux Civils de Colmar, Colmar, France
⁴Laboratoire d'Hématologie Cellulaire, Faculté de Médecine, Strasbourg, France

1481

The Amount of Mitochondrial Apoptosis Exerts Prognostic Impact on Normal Karyotype Acute Myeloid Leukemia

Giovanni Del Poeta¹, Maria Ilaria Del Principe¹^*, Francesco Buccisano¹^*, Luca Maurillo¹^*, Benedetta Neri¹^*, Licia Ottaviani¹^*, Fabrizio Luciano¹^*, Daniela Piccioni¹^*, Maria Irno Consalvo¹^*, Emanuele Ammatuna¹^*, Antonio Bruno¹^*, Paolo de Fabritiis¹^*, Valter Gattei²^*, Adriano Venditti¹^*, Francesco Lo Coco¹^* and Sergio Amadori¹^*

¹Hematology, University Tor Vergata, Rome, Italy
²Clinical and Experimental Hematology Research Unit, Centro di Riferimento Oncologico, Aviano (PN), Italy

1482

Histone H4 Acetylation as a Prognostic Factor for Patients with Acute Lymphocytic Leukemia in First Relapse

Anjali Advani, MD¹, Sarah Gibson, MD²^*, Elizabeth Douglas, MD²^*, Tao Jin³^*, Matt Kalaycio, MD¹, Edward A. Copelan, MD¹, Mikkael A Sekeres, MD, MS¹, Ronald Sobecks, MD¹, Shawnda Sungren¹^* and Eric Hsi, MD²

¹Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
²Clinical Pathology, Cleveland Clinic, Cleveland, OH
³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

1483

FISH and SNP-Array Karyotyping Improve the Detection of Recurrent Chromosomal Defects Including Del(5q), Monosomy 7, Del(7q), Trisomy 8, and Del(20q) in Myelodysplastic Syndromes

Hideki Makishima, MD, PhD¹, Manjot Rataul, MD¹^*, Lukasz P. Gondek, MD, PhD¹^*, Jungwon Huh, MD¹^*, James R. Cook, MD, PhD², Karl S. Theil, MD³, Mikkael A Sekeres, MD, MS⁴, Elizabeth Kuczkowski⁵^* and Jaroslaw P. Maciejewski, MD, PhD⁶

¹Exp. Hem. & Hematopoiesis, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
²Cleveland Clinic Foundation, Cleveland, OH
³The Cleveland Clinic Foundation, Cleveland, OH
⁴Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁵Celgene Corporation, Summit, NJ
⁶Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1484

High-Resolution Genomic Profiling (array-CGH) of Childhood T-ALL Identifies Deletions at 6q15-16.1 as a Predictive Marker for Early Treatment Response

Marc Remke¹^*, Stefan Pfister²^*, Martin Stanulla³^*, Martin Schrappe⁴, Martina Ulrike Muckenthaler²^*, Peter Lichter¹^* and Andreas Kulozik²

¹Division Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
²Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany
³Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
⁴Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

1485

Genomic Profiling helps to Predict Treatment Response and Outcome in Relapsed Childhood ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia

Almut Giese¹^*, Reinhard Ullmann, PhD²^*, Cornelia Eckert, PhD¹^*, Renate Kirschner-Schwabe, PhD¹^*, Guenter Henze, MD¹^* and Karl Seeger, MD, PhD³^*

¹Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany
²Molecular Cytogenetics, Max-Planck Institute for Molecular Genetics Berlin, Berlin, Germany
³Department of Pediatric Oncology/Hematology, Charité - Medical University, Berlin, Germany

1486

OCT-2 Expression and OCT-2/ BOB.1 Co-Expression Predict Prognosis in Patients with Newly Diagnosed Acute Myelogenous Leukemia

Kathleen Lim, MD¹^*, Sarah Gibson, MD²^*, Tao Jin³^*, Eric Hsi, MD², Matt Kalaycio, MD¹, Edward A. Copelan, MD¹, Mikkael A. Sekeres, MD, MS¹, Ronald Sobecks, MD¹ and Anjali Advani, MD¹

1487

Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML

Lars Bullinger¹, Thomas Hielscher²^*, Ursula Botzenhardt¹^*, Sabrina Heinrich¹^*, Richard Schlenk¹, Jonathan R. Pollack³^*, Konstanze Dohner¹^*, Axel Benner²^* and Hartmut Dohner¹^*

¹Internal Medicine III, University of Ulm, Ulm, Germany
²Biostatistics, DKFZ, Heidelberg
³Pathology, Stanford Univ., Stanford, CA

1488

Analysis of Clonal T-Cell Receptor Gamma Gene Rearrangements, NOTCH1, FBW7 and PTEN Mutations in Paired Pediatric T-Cell Acute Lymphoblastic Leukemia Samples at Diagnosis and Relapse Reveals Evidence of Relapse in New Leukemic Clones

Qing Chen, MD¹^*, Amanda Larson Gedman²^*, Larry H. Matherly, PhD³^* and Jeffrey W. Taub, MD⁴

¹Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute; Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI
²Graduate Program in Cancer Biology, Wayne State University School of Medicine, Detroit, MI
³Barbara Ann Karmanos Cancer Institute, Detroit, MI
⁴Children's Hosp. of Michigan, Detroit, MI

1489

Prognostic Impact of Peripheral Blood Involvement during Early Time Points of Childhood ALL Treatment

Jana Volejnikova, MD¹^*, Eva Fronkova, MD, PhD¹^*, Ester Mejstrikova, MD¹^*, Katerina Muzikova¹^*, Leona Reznickova¹^*, Dagmar Pospisilova, MD²^*, Jaroslav Sterba, MD, PhD³^*, Yahia Jabali, MD⁴^*, Daniela Prochazkova, MD⁵^*, Bohumir Blazek, MD⁶^*, Jiri Hak, MD⁷^*, Zdenka Cerna, MD⁸^*, Jan Stary, MD, PhD⁹^* and Jan Trka, MD, PhD¹

¹Pediatric Hematology and Oncology, 2nd Medical School, Charles University Prague, CLIP - Childhood Leukemia Investigation Prague, Prague, Czech Republic
²Pediatrics, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
³Pediatric Oncology, University Hospital Brno, Brno, Czech Republic
⁴Pediatrics, Ceske Budejovice Hospital, Ceske Budejovice, Czech Republic
⁵Pediatrics, Masaryk Hospital Usti nad Labem, Usti nad Labem, Czech Republic
⁶Pediatrics, University Hospital Ostrava, Ostrava, Czech Republic
⁷Pediatrics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
⁸Pediatrics, University Hospital Plzen, Plzen, Czech Republic
⁹Pediatric Hematology and Oncology, Charles University, University Hospital Motol, Prague, Czech Republic

1490

A Rapid Flow Cytometric Method for the Detection of NPM1 Mutated Patients with Acute Myeloid Leukemia (AML)

Uta Oelschlaegel, PhD^*, Sina Koch, PhD^*, Markus Schaich, MD^*, Frank Kroschinsky, MD^*, Stefani Parmentier, MD^*, Gerhard Ehninger, MD and Christian Thiede, MD^*

Hematology, University Hospital, Dresden, Germany

1491

Acute Lymphoblastic Leukemia with “Normal” Karyotype is not without Genomic Aberrations

Anu Usvasalo¹^*, Riikka Räty²^*, Arja Harila-Saari³^*, Pirjo Koistinen⁴^*, Eeva-Riitta Savolainen⁵^*, Kim Vettenranta¹, Sakari Knuutila⁶^*, Erkki Elonen²^* and Ulla M. Saarinen-Pihkala¹^*

¹Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
²Department of Hematology, Helsinki University Central Hospital, Helsinki, Finland
³Department of Pediatrics, Oulu University Hospital, Oulu, Finland
⁴Department of Internal Medicine, Oulu University Hospital, Oulu, Finland
⁵Department of Clinical Chemistry, Oulu University Hospital, Oulu, Finland
⁶Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland

1492

Defining the Landscape of Resistance Mutations in the Context of Modern Treatment Protocols for Acute Promyelocytic Leukemia (APL)

Jelena V Jovanovic¹^*, Fabien Guidez¹^*, Farhad Ravandi²^*, Estelle Duprez³^*, Mukunder Patel¹^*, Ken Mills⁴^*, Steven Kornblau²^*, Maadh Aldouri⁵^*, Martin Auger⁶^*, Alan K Burnett⁷^*, Ellen Solomon¹^* and David Grimwade¹

¹Dept of Medical & Molecular Genetics, King's College London, London, United Kingdom
²Dept of Leukemia, MD Anderson Cancer Center, Houston, TX
³Centre d'Immunologie Marseille Luminy, France
⁴Queens University Belfast, United Kingdom
⁵Dept Haematology, Medway Maritime Hospital, Gillingham, United Kingdom
⁶Dept Haematology, Norfolk & Norwich University Hospital, United Kingdom
⁷Dept Haematology, University of Wales, Cardiff, United Kingdom

1493

Notch Pathway Activation by a Combination of Activating NOTCH1-Receptor and Inactivating FBXW7 Mutations Robustly Predicts Excellent Early Treatment Response in Pediatric T-ALL

Corinne Kox¹^*, Svenja Leible²^*, Stephen Breit²^*, Martin Stanulla, MD³^*, Martin Schrappe, MD⁴, Martina Ulrike Muckenthaler²^* and Andreas Kulozik²

¹Molecular Medicine Partnership Unit, EMBL and Medical Faculty, University of Heidelberg, Heidelberg, Germany
²Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany
³Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
⁴Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

1494

NOTCH1/FBXW7 Mutation Identifies a Large Subgroup with Favorable Outcome in Adult T-ALL: A GRAALL Study

Vahid Asnafi¹^*, Agnes Buzyn¹^*, Sandrine Lenoir¹^*, Fréderic Baleydier¹^*, Arnauld Simon¹^*, Kheira Beldjord¹^*, Oumedaly Reman²^*, Francis Witz³^*, Thierry de Revel⁴^*, Emmanuelle Tavernier⁵^*, Pascal Turlure⁶^*, Thibaut Leguay⁷^*, Francoise Huguet⁸^*, Jean-Paul Vernant⁹^*, Veronique Lhéritier¹⁰^*, Marie-Christine Béné³^*, Norbert Ifrah¹¹^*, Xavier Thomas¹², Hervé Dombret¹³ and Elizabeth MacIntyre, PhD¹⁴^*

¹Department of Hematology, INSERM EMI0210, Hôpital Necker, AP-HP, Paris, France
²CHU, Caen, France
³CHU, Nancy, France
⁴Hôpital Percy, Clamart, France
⁵CHU, Saint-Etienne, France
⁶CHU, Limoges, France
⁷Hôpital Haut-Lévèque, Bordeaux, France
⁸CHU, Toulouse, France
⁹Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
¹⁰GRAALL office, Hôpital Edouard Herriot, Lyon, France
¹¹CHU, Angers, France
¹²Hôpital Edouard Herriot, Lyon, France
¹³Hôpital Saint-Louis, AP-HP, Paris, France
¹⁴MILE Study Group, on Behalf of European LeukemiaNet (ELN, WP13), Munich, Germany

1495

Hierarchical Cluster Analysis of Immunophenotype in AML Patients with NPM1 Gene Mutation Reveals Two Distinct Groups with Different Prognosis

Chien-Yuan Chen¹^*, Liang-In Lin, PhD², Wen-Chien Chou³, Woei Tsay¹^*, Jih-Luh Tang¹^*, Sheng-Yi Huang¹^* and Hwei-Fang Tien¹

¹Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
²Clin Lab Sci and Med Biotech, National Taiwan University, Taipei, Taiwan
³Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

1496

CALM-AF10 Positive Acute Myeloid Leukemias : A French Cohort of 18 Patients

Cecile Borel¹^*, Nicole Dastugue²^*, Thomas Prebet, MD³^*, Norbert Vey, MD⁴, Marie-Joelle Mozziconacci⁵^*, Christian Bastard⁶^*, Christine Lefebvre⁷^*, Francine Mugneret⁸^*, Dominique Leroux⁷^*, Faezeh Legrand⁹^*, Marie Agnes Collonges Rame⁹^*, Sorin Visanica¹⁰^*, Jean Philippe Rault¹¹^*, Nathalie Gachard¹²^*, Arnaud Pigneux, MD, PhD¹³^*, Eric Lippert¹⁴^*, Sylvie Taviaux¹⁵^*, Pascaline Talmant¹⁶^*, Murielle Roussel¹^*, Françoise Huguet¹^*, Eric Delabesse, PhD²^* and Christian Recher¹^*

¹Service d'Hematologie, CHU Toulouse, Toulouse, France
²Laboratoire d'Hématologie, Hôpital Purpan, Toulouse, France
³Molecular Pharmacology, INSERM U891 Centre de Recherche en CancÃƒÂ©roligie de Marseille, Marseille, France
⁴Dept. of Hematology, Institut Paoli Clamettes, Marseille, France
⁵IPC, Marseille, Marseille, France
⁶Hematology, INSERM U918, Centre Henri Becquerel, Rouen, France
⁷Hematologie cellulaire et moleculaire, CHU Grenoble, Grenoble, France
⁸Laboratoire de Cytogénétique, CHU Dijon, Dijon, France
⁹Hematology, INSERM UMR645 - CHU Jean Minjoz, BesanÃ§on
¹⁰Hématologie clinique, CHR METZ-THIONVLLE, Metz, France
¹¹Laboratoire de biologie, Hôpital Legouest, Metz Armées, France
¹²Hopital de Limoges
¹³Service d'Hematologie, CHU Bordeaux, Hopital HAUT-LEVEQUE, Pessac, France
¹⁴HÃ©matopoÃ¯ése leucÃ©mique, UniversitÃ© Victor Segalen, Bordeaux, France
¹⁵Laboratoire de génétique moléculaire et chromosomique, CHU Arnaud-de-Villeneuve Montpellier, Montpellier
¹⁶Hematology, CHU Hotel-Dieu, Nantes, France

1497

Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability

Ilaria Iacobucci¹^*, Annalisa Lonetti¹^*, Anna Ferrari¹^*, Simona Soverini¹^*, Emanuela Ottaviani¹^*, Daniela Cilloni²^*, Sabina Chiaretti³^*, Nicoletta Testoni¹^*, Cristina Papayannidis¹^*, Francesca Messa²^*, Federica Salmi¹^*, Antonella Vitale³^*, Francesca Paoloni⁴^*, Francesca Arruga²^*, Panagiota Giannoulia¹^*, Marco Vignetti⁴^*, Fabrizio Pane⁵^*, Pier Paolo Piccaluga¹, Alessandra Gnani¹^*, Stefania Paolini¹^*, Giuseppe Saglio²^*, Michele Baccarani¹, Robert Foà³ and Giovanni Martinelli¹^*

¹Department of Hematology/Oncology L. and A. Seràgnoli, University of Bologna, Bologna, Italy
²Department of Clinical and Biological Science, University of Turin, Orbassano, Turin, Italy
³“Sapienza” University of Rome, Dept. of Cellular Biotechnologies and Hematology, Rome, Italy
⁴GIMEMA Data Center, GIMEMA Foundation, Rome, Italy
⁵CEINGE- Biotecnologie Avanzate, University of Naples Federico II, Naples, Italy

1498

Increase in the Incidence of Secondary Acute Myeloid Leukemia (2-AML): A Single Institution Experience Over 20 Years

Elias Jabbour¹^*, Hagop M Kantarjian², Sherry Pierce³^*, Guillermo Garcia-Manero¹^*, Jorge Cortes, MD³, Stefan Faderl, MD³ and Farhad Ravandi³^*

¹Leukemia, M.D. Anderson Cancer Center, Houston, TX
²The University of Texas M. D. Anderson Cancer Center, Houston, TX
³M.D. Anderson Cancer Center, Houston, TX

1499

Bcl2, a Candidate Murine Therapy-Related Acute Myeloid Leukemia Susceptibility Factor, Exhibits Strain-Dependent and Alkylator-Responsive Expression

Ryan Funk, BS^*, Patrick Cahan^*, Masayo Izumi^* and Timothy Graubert, MD

Internal Medicine - Stem Cell Biology, Washington University in Saint Louis, School of Medicine, Saint Louis, MO

1500

Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se

Elisabeth Paietta¹, Xiaochun Li, Ph.D.²^*, Sue Richards³^*, Janis Racevskis, Ph.D.¹^*, Gordon W. Dewald, PhD, PhD, FACMG⁴, Jacob M. Rowe, MD⁵, Martin S Tallman⁶, Hillard M Lazarus, MD⁷^*, Mark R. Litzow, MD⁴, Anthony H. Goldstone, FRCP, FRCPath⁸ and Peter Wiernik, MD¹^*

¹Cancer Center, Montefiore Medical Center North Division, Bronx, NY
²Division of Biostatistics, Indiana University, Indianapolis, IN
³Ctsu, University of Oxford, Oxford, United Kingdom
⁴Mayo Clinic, Rochester, MN
⁵Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and Technion, Israel Institute of Technology, Haifa, Israel., Haifa, Israel
⁶Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
⁷Ireland Cancer Center, University Hospitals of Cleveland, Cleveland, OH
⁸Univ. College London Hosp., London, ARRAY(0xc1581ac)

1501

Chromosome 17 Abnormalities Are Associated with Worse Overall and Relapse Free Survival in Patients with Acute Myelogenous Leukemia and Poor-Risk Cytogenetics

Gautam Borthakur, MD¹, Constantine Tam²^*, Hagop Kantarjian²^*, E. Lin³^*, Jorge Cortes²^*, Susan O'Brien²^*, Charles Koller²^*, Sherry Pierce²^* and Michael Keating²^*

¹Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
²Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX
³Quantitative Sciences Division, U.T. M.D. Anderson Cancer Center, Houston, TX

1502

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422

Robert E Gallagher, MD¹, Esther L Schachter-Tokarz, BA²^*, Lawrence E. Morris³, Tianna Dauses, BSN⁴^*, Ivana Gojo, MD⁵, Marcel P. Devetten, MD⁶, Katarzyna Jamieson, MD⁷, Robert L. Redner, MD⁸, Mikkael A. Sekeres, MD, MS⁹, Ibitayo Owoeye, MD⁴^* and Steven D. Gore, MD⁴

¹Medicine and Oncology, Albert Einstein Cancer Center, Bronx, NY
²Oncology, Albert Einstein Cancer Center, Bronx, NY
³BMT Group of Georgia, Atlanta, GA
⁴The Sidney Kimmel Comprehensive Cancer Ctr. at Johns Hopkins, Baltimore, MD
⁵University of Maryland Medical Center, Baltimore, MD
⁶Lied Transplant Center 8718, UNMC, Omaha, NE
⁷University of Florida, Gainesville, FL
⁸Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA
⁹Hematologic Oncology and Blood Disorders R35, Cleveland Clinic, Cleveland, OH

1503

The Level of AKT Phosphorylation on Threonine 308 but Not on Serine 473 Is Associated with High-Risk Cytogenetics and Predicts Poor Overall Survival in Acute Myeloid Leukemia

Nathalie Gallay, PhD¹^*, Cédric Dos Santos¹^*, Lise Cuzin, MD²^*, Marina Bousquet¹^*, Violaine Simonnet Gouy³^*, Claire Chaussade, PhD⁴^*, Michel Attal, MD⁵, Bernard Payrastre, PhD¹^*, Cecile Demur, MD⁶^* and Christian Recher, MD, PhD⁷^*

¹Centre de Physiopathologie de Toulouse Purpan et Université Paul Sabatier, Département d'Oncogenèse, Signalisation et Innovation, Inserm U563, Toulouse
²Service des Maladies Infectieuses et Tropicales, CHU Toulouse
³CHU Toulouse, Toulouse, France
⁴Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences University of Auckland New Zealand, Auckland, New Zealand
⁵Hopital Purpan, Toulouse, France
⁶Laboiratoire d'Hématologie, CHU Toulouse, Inserm U563, Toulouse, France
⁷Service d'Hématologie, CHU Toulouse, Inserm U563, Toulouse, France

1504

Using Combined High Density SNP/CNV Arrays as a Clinical Karyotyping Tool in Myeloid Malignancies

Jungwon Huh, MD¹^*, Lukasz Gondek²^*, Christine O'Keefe, PhD³^*, Karl S. Theil, MD⁴ and Jaroslaw P. Maciejewski, MD, PhD⁵

¹Exp. Hem. & Hematopoiesis, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
²Exp. Hem. & Hematopoiesis, Experimental Hematology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
³Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH
⁴Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, OH
⁵Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

1505

BIM Regulates Prednisolone-Induced Apoptosis in B-Lineage ALL: A Potential Biomarker

Nan Jiang, PhD¹^*, Grace Shi Min Koh, BSc²^*, Shirley Kow Yin Kham, BSc¹^*, Yi Lu, PhD¹^*, Fook Tim Chew, PhD²^* and Allen Eng Juh Yeoh, MD¹^*

¹Department of Paediatrics, National University of Singapore, Singapore, Singapore
²Department of Biological Sciences, National University of Singapore, Singapore, Singapore

1506

Prevalence and Clinical Correlates of JAK2 Mutations in Pediatric Down Syndrome Acute Lymphoblastic Leukemia

Amos S. Gaikwad, PhD¹^*, Cassia L. Rye¹^*, Meenakshi Devidas, PhD²^*, Shai Izraeli Sr., MD³^*, Sharon E. Plon, MD, PhD¹^*, Giuseppe Basso, MD⁴^*, Andrea Pession, MD, PhD⁵ and Karen R. Rabin, MD⁶

¹Baylor College of Medicine, Houston, TX
²Department of Epidemiology & Health Policy Research, University of Florida College of Medicine, Gainesville, FL
³Pediatric Hematology-Oncology and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel
⁴Dept. Pediatrics, University of Padova, Padova, Italy
⁵Oncologia-Ematologia Pediatrica, Santorsola-Malpicitci, Bologna, Italy
⁶Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX

1507

GATA-2 L359V Mutation Is Solely Associated with Cml progression but Not Other Hematological Malignancies

Su-Jiang Zhang¹^* and Jing-Yi Shi²^*

¹Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
²Shanghai Institute of Hematology, Shanghai, China

1508

MRD Monitoring of Childhood ALL Using Hierarchical Clustering and Support Vector Machine Learning of Complex Multi-Parameter Flow Cytometry Data

Karel Fiser, PhD¹^*, Tomas Sieger, MSc²^*, Angela Schumich³^*, Julie Irving, PhD¹, Michael N Dworzak, MD³^* and Josef Vormoor, MD, FRCPCH¹

¹Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
²Praha, Czech Republic
³Children's Cancer Research Institute, Vienna, Austria

1509

Identification of Gene Expression Signatures Accurately Predicting Cytogenetic Subtypes in Pediatric Acute Myeloid Leukemia

Brian V Balgobind, MD¹^*, Marry M van den Heuvel-Eibrink, MD, PhD¹^*, Renee X Menezes¹^*, Dirk Reinhardt, MD, PhD², Iris H.I.M. Hollink, MD¹^*, Susan T.J.C.M. Arentsen-Peters¹^*, Elisabeth R van Wering³, Gertjan Kaspers, MD, PhD⁴, Jaqueline Cloos, PhD⁴^*, Eveline S.J.M de Bont⁵^*, Andre Baruchel, MD⁶, Jean-Michel Cayuela, PhD⁶^*, Jan Stary, MD, PhD⁷^*, Jan Trka, MD., PhD⁸^*, Berna Beverloo, PhD⁹^*, Rob Pieters, Prof.¹^*, Christian M Zwaan, MD, PhD¹⁰ and Monique L. Den Boer, MSc, PhD¹

¹Department of Pediatric Hematology/Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
²Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany
³Dutch Childhood Oncology Group (DCOG), The Hague, Netherlands
⁴VU University Medical Center, Amsterdam, Netherlands
⁵Division of Pediatric Oncology/Hematology, Department of Pediatrics,, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen Groningen, Groningen, Netherlands
⁶Dept. of Pediatric Hematology, Hopital Saint Louis, Paris, France
⁷Dept of Pediatric Hematology and Oncology, 2nd Medical School, Charles University, University Hospital Motol, Prague, Czech Republic
⁸Pediatric Hematology/Oncology, Charles University, University Hospital Motol, Prague, Czech Republic
⁹Clinical Genetics, Erasmus MC, Rotterdam, Netherlands
¹⁰Department of Pediatric Hematology/Oncology, ErasmusMC Rotterdam-Sophia Children's Hospital, Rotterdam, Netherlands

1510

Distribution and Outcome According to Cytogenetics in 502 Paediatric AML Patients Treated in Study AML-BFM 98

Christine von Neuhoff, MD¹^*, Jutta Bradtke²^*, Martin Zimmermann, PhD¹^*, Jean-Pierre Bourquin, MD, PhD³^*, David Betts, BSc⁴^*, Jan Stary, MD, PhD⁵^*, Zuzana Zemanova, MD⁶^*, Michael N Dworzak, MD, PhD⁷^*, Dirk Reinhardt, MD, PhD¹ and U. Creutzig⁸

¹Paediatric Haematology/Oncology, Hannover Medical School, Hannover, Germany
²Paediatric Haematology/Oncology, Justus-Liebig-Universität Giessen, Oncogenetic laboratory, Giessen, Germany
³Paediatric Haematology/Oncology, University of Zurich, Zurich, Switzerland
⁴National Centre for Medical Genetics, Our Lady's Children's Hospital, Dublin 12, Ireland
⁵Dept of Pediatric Hematology and Oncology, 2nd Medical School, Charles University, University Hospital Motol, Prague, Czech Republic
⁶Cytogenetics, General Faculty Hospital, Charles University, Prague, Czech Republic
⁷Children's Cancer Research Institute and St. Anna Children's Hospital, Vienna, Austria
⁸BFM-G, Germany

1511

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study

Andrea Biondi¹, André Schrauder²^*, Maria Grazia Valsecchi³^*, Claus R Bartram⁴^*, Georg Mann⁵^*, Giulio De Rossi⁶, Anja Möricke⁷^*, Rosanna Parasole⁸^*, Jochen Harbott⁹, Chiara Messina¹⁰^*, C. Rizzari¹¹^*, Giuseppe Masera¹²^* and Martin Schrappe²

¹Pediatric Clinic, M. Tettamanti Research Center, University of Milano-Bicocca, Monza, Italy
²Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
³Medical Statistics Unit, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy
⁴Institute of Human Genetics, Ruprecht-Karls University, Heidelberg, Germany
⁵St. Anna Children's Hospital, Vienna, Austria
⁶Department of Pediatric Hematology, Ospedale Bambin GesÃ¹, Rome, Italy
⁷Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
⁸Department of Pediatric Hematology-Oncology, Ospedale Pausillipon, Napoli, Italy
⁹Ped. Hematol./Oncol., Oncogenetic Laboratory, Children's University Hospital Giessen, Giessen, Germany
¹⁰Department of Pediatrics, Pediatric Hematology Oncology, Padova, Italy
¹¹University of Milano - Bicocca, Monza, Italy
¹²Pediatric Clinic, University of Milano-Bicocca, Monza, Italy

1512

Low Frequency of MLL-PTD Detected in Pediatric Acute Myeloid Leukemia Using MLPA Screening

Brian Balgobind, MD¹^*, Iris H.I.M. Hollink, MD¹^*, Dirk Reinhardt, MD, PhD², Elisabeth R van Wering³, Siebold S.N. de Graaf, MD, PhD³^*, Andre Baruchel, MD⁴, Jean-Michel Cayuela, PhD⁴^*, Rob Pieters, Prof.¹^*, Christian M Zwaan, MD, PhD⁵ and Marry M van den Heuvel-Eibrink, MD, PhD¹^*

1513

High Resolution Karyotyping of Large Granular Lymphocyte Leukemia by SNP Arrays Reveals Clonal Defects Leading to LOH at Loci Integral to Lymphocyte Function

Aaron D. Viny, BS¹^*, Hideki Makashima²^*, Jungwon Huh²^*, Karl S. Theil, MD³, Lukasz Gondek, MD²^* and Jaroslaw Maciejewski²

¹Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH
²Experimental Hematology and Hematopoiesis Section, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
³The Cleveland Clinic Foundation, Cleveland, OH

1514

Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children's Oncology Group Trials

David R. Czuchlewski¹^*, Richard C. Harvey¹, I-Ming Chen¹, Ali Bourguet-Vincent¹^*, Bradley Rodgers¹^*, Richard Vestal¹^*, Kerem Ar¹^*, Huining Kang¹^*, Carla S. Wilson¹, Eric C. Larsen²^*, Stephen P. Hunger², Mignon Loh², Meenakshi Devidas²^*, Elizabeth Raetz², Gregory Reaman², William L. Carroll², Naomi Winick² and Cheryl L. Willman¹

¹University of New Mexico Cancer Center, Albuquerque, NM
²Children's Oncology Group, Arcadia, CA

1515

Prevalence of EVI1 Overexpression and Its Impact on Diagnosis and Prognosis in Acute Myeloid Leukemia: A Study of 490 Patients from the Spanish Group of Myeloid Malignancies of the RTICC

Iria Vazquez, BSc¹^*, José Cervera, MD, PhD²^*, Maria Gomez-Benito, Ph.D.¹^*, Nerea Marcotegui, BSc¹^*, Miren Maicas, BSc¹^*, Ana Conchillo, Ph.D.¹^*, Ana Valencia, Ph.D.²^*, Eva Lumbreras, Ph.D.³^*, Salut Brunet, MD⁴^*, Maria T. Gómez-Casares, MD, Ph.D.⁵^*, Jesus-Maria Hernandez-Rivas, MD, Ph.D.³^*, Maria J. Calasanz, PhD⁶^*, Jorge Sierra, MD, PhD⁴^* and Maria D. Odero, MD, PhD¹

¹Oncology Division, CIMA, University of Navarra, Pamplona, Spain
²Hematology, Hospital Universitario La Fe, Valencia, Spain
³Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
⁴Division of Clinical Hematology, Hospital de Santa Creu i Sant Pau, Barcelona, Spain
⁵Hematology, Hospital Dr. Negrin, Las Palmas de Gran Canaria, Spain
⁶Genetics, University of Navarra, Pamplona, Spain

1516

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens: Results of the Medical Research Council Trial UKALL2003

Robert J Cutting¹^*, Sue Richards²^*, Jeremy Hancock³^*, Nicholas Goulden⁴^*, Christopher D Mitchell⁵^* and Ajay J. Vora⁶

¹Department of Haematology, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom
²Ctsu, University of Oxford, Oxford, United Kingdom
³Bristol Genetics Laboratory, Bristol MRD Group, Bristol, United Kingdom
⁴GOSH, London
⁵Department of Paediatric Oncology, John Radcliffe Hospital, Oxford, United Kingdom
⁶Dept. of Pediatric Hematology, The Children's Hospital, Sheffield, United Kingdom

1517

Chromosome 14 Copy Number-Dependent IGH Gene Rearrangement Patterns in High Hyperdiploid Childhood B Cell Precursor ALL: Implications for Leukemia Biology and Minimal Residual Disease Analysis

Eva Csinady¹^*, Vincent van der Velden²^*, Ulrike Kaindl¹^*, Ruth Joas¹^*, Jelteje de Vries²^*, Berna Beverloo³^*, Jacques van Dongen²^*, Georg Mann⁴^*, Oskar A. Haas⁴ and Renate Panzer-Grümayer⁵^*

¹CCRI, Vienna, Austria
²Erasmus MC, Rotterdam
³Clinical Genetics, Erasmus MC, Rotterdam, Netherlands
⁴St. Anna Kinderspital, Vienna, Austria
⁵CCRI and St. Anna Kinderspital, Vienna, Austria

1518

The Prognostic Value of JAK2 Exon 16 Mutations in Children with Down Syndrome and Acute Lymphoblastic Leukemia

T. Buitenkamp, MSc¹^*, A. A. Danen-van Oorschot, PhD¹^*, M. Van Den Heuvel-Eibrink, MD, PhD¹^*, E. van Wering², R. Pieters, MD, PhD¹ and C. M Zwaan, MD, PhD¹

¹Dept. of Pediatric Hem./Onc, Erasmus MC, Rotterdam, Netherlands
²Dutch Childhood Oncology Group (DCOG), The Hague, Netherlands

1519

Decisional Algorithm to Incorporate Hematopoietic Stem Cell Transplantation in the Management of Adult Patients with Acute Myeloid Leukaemia

Francesco Buccisano, M.D., Luca Maurillo^*, Maria Ilaria Del Principe^*, Giovanni Del Poeta^*, Paola Panetta^*, Emanuele Ammatuna^*, Licia Ottaviani^*, Chiara Sarlo^*, Micol Quaresima^*, Gottardo De Angelis^*, Manuela Rizzo^*, Selenia Campagna^*, Francesco Lo Coco^*, William Arcese^*, Sergio Amadori^* and Adriano Venditti^*

Hematology, University Tor Vergata, Roma, Italy

1520

Comparison of the Predictive Value of MRD and PVA Score in Pediatric ALL

Anja Troeger, MD¹, Gabriele Escherich, MD²^*, Udo zur Stadt, PhD²^*, M. L Den Boer, MSc, PhD³, Rob Pieters, MD, PhD⁴, Martin Zimmermann, PhD⁵^*, Ulrich Göbel, MD, PhD¹^*, Arndt Borkhardt, MD, PhD¹^*, Dagmar Dilloo, MD, PhD⁶^* and Gritta Janka, MD, PhD⁷

¹University Hospital Duesseldorf, Clinic for Pediatric Oncology, Hematology, and Clinical Immunology, Duesseldorf, Germany
²Universitätsklinikum Hamburg-Eppendorf, Germany
³Dept. of Pediatric Onc./Hem., Erasmus Medical Center, Rotterdam, Netherlands
⁴Dept. of Pediatric Hem./Onc., Erasmus MC, Rotterdam, Netherlands
⁵Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
⁶Heinrich-Heine University, Dusseldorf, Germany
⁷Hematology & Oncology, Children's University Hospital, Hamburg, Germany

1521

Precursor T Cell Acute Lymphoblastic Leukemia (T-ALL) Blasts Lose Expression of Markers of Immaturity during Chemotherapy: Implications for the Detection of Minimal Residual Disease

Mikhail Roshal, MD, PhD¹^*, Jonathan Fromm, MD, PhD², Stuart Winter, MD³, Kimberly Dunsmore, MD⁴ and Brent Wood, MD, PhD⁵

¹Laboratory Medicine, University of Washington, Seattle, WA
²Laboratory Medicine, University of Washington, Seattle
³Department of Pediatrics, University of New Mexico, Albuquerque, NM
⁴Health Sciences Center, University of Virginia, Charlottesville, VA
⁵Seattle Cancer Care Alliance, Seattle, WA

1522

Childhood Acute Lymphoblastic Leukemia: High Genomic Stability from Initial Diagnosis to Early Relapse

Barbara Meissner, MD¹^*, Cornelia Eckert, PhD²^*, Anja Moericke, MD³^*, Arend von Stackelberg, MD²^*, Renate Kirschner-Schwabe, PhD²^*, Gunnar Cario, MD³^*, André Schrauder, MD³^*, Martin Zimmermann, PhD¹^*, Karl Welte, MD¹, Martin Schrappe, MD³ and Martin Stanulla, MD, MSc¹^*

¹Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
²Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany
³Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

1523

Mutations in Mitochondrial DNA Is An Adverse Factor for Survival in Patients with Acute Myeloid Leukemia

Trine Silkjaer¹^*, Anni Aggerholm¹^*, Charlotte Guldborg Nyvold¹^*, Peter Hokland, M.D.² and Jan Maxwell Norgaard¹^*

¹Department of Hematology, Aarhus University Hospital, Aarhus Sygehus, 8000 Aarhus C, Denmark
²Department of Hematology, Aarhus University Hospital, Aarhus Sygehus, Aarhus, Denmark

1524

The Leukemia-Associated Antigen PRAME Is Overexpressed in Myeloid Leukemias and Inhibits Cell Differentiation by Blocking the Receptor for Retinoic Acid (RAR)-Signaling in Vitro and Is Therefore a Interesting Candidate for Targeted Immunotherapies

Jochen Greiner^*, Lars Bullinger, Krzysztof Giannopoulos^*, Anita Schmitt^*, Marlies Goetz^*, Lena Kienle^*, Hartmut Döhner and Michael Schmitt

Dept. of Internal Medicine III, University of Ulm, Ulm, Germany

1525

Incidence and Prognostic Impact of Gene Mutations in Older Patients with AML Treated in the ALFA-9801 Study

Aline Renneville¹^*, Sylvie Castaigne²^*, Sylvie Chevret³^*, Laura Llopis¹^*, Nathalie Philippe¹^*, Olivier Nibourel¹^*, Sandrine Hayette⁴^*, Jean-Michel Cayuela³^*, Dina Naguib⁵^*, Nathalie Gachard⁶^*, Dominique Bories⁷^*, Christian Bastard⁸^*, Fatiha Merabet²^*, Cécile Pautas⁷^*, Christine Terré²^*, Xavier Thomas⁹, Hervé Dombret³ and Claude Preudhomme¹^*

¹Laboratoire d'Hématologie, CHRU, Lille, France
²Hôpital Mignot, Versailles, France
³Hôpital Saint-Louis, AP-HP, Paris, France
⁴Hôpital Edouard Herriot, Lyon, France
⁵CHU, Caen, French Guiana
⁶CHU, Limoges, France
⁷Hôpital Henri Mondor, AP-HP, Créteil, France
⁸Centre Henri Becquerel, Rouen, France
⁹Hopital Edouard Herriot, Lyon, France

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

611.P1.99 Leukemias - Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis Poster I